Form 4 for HCWB HCW Biologics Inc.
Accepted 2026-07-31 16:06:15 ET · period of report 2026-07-29 · accession 0001493152-26-035631 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-31 16:06 | 2026-07-29 | HCWB | Flowers Lee | SVP of Business Development | P - Purchase | $2.58 | +7,736 | 8,691 | +810% | +$20.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-07-29 | P | A | 7,736 | $2.58 | 8,691 | D | — | — | (F1) The reporting person purchased these shares directly from the issuer in a private placement under a Securities Purchase Agreement dated July 29, 2026 ("SPA"), which purchase is exempt from the registration requirements of Section 5 of the Securities Exchange Act of 1934, as amended, pursuant to Section 4(a)(2) thereof and/or Rule 506(b) of Regulation D thereunder. Additionally, the reporting person is entitled to receive common warrants exercisable for an aggregate of up to 7,736 shares of common stock. Under the terms of the SPA, issuance of the common warrants is subject to stockholder approval under Nasdaq Listing Rule 5635(d). Upon issuance, the common warrants will be exercisable immediately and expire 5.5 years from date of issuance. |